Go back

Go to
Jean-Yves Desmottes

“Numerous members of our team have extensive industrial and operational experience, having served as CEOs within the healthcare industry. This hands-on experience in the field synergizes seamlessly with the scientific and financial expertise present within our team. Together, we create tailor-made strategies, enhance performance, and generate value positively impacting the healthcare industry.”



Sector: Consumer Health


Jean-Yves Desmottes joined ARCHIMED as an Operating Partner in 2019, prior to that he was working with ARCHIMED as a MedTalent® and then as a Strategic Partner. He was later appointed as Partner in 2021. Jean-Yves has extensive experience in the consumer health sector with notable achievements in corporate strategy and business development.

Prior to joining ARCHIMED, Jean-Yves held the dual positions of Vice President of NAOS Group since 2014 and General Manager of Laboratoires Dermatologiques Bioderma since 2006. At NAOS, Jean-Yves was responsible for the operations & NAOS brands, the processing and organization of NAOS Group’s global support functions and building the group’s strategic plan. At Bioderma, he was responsible for leading and implementing the strategic business development plan.

In 2002, Jean-Yves joined Laboratoires Bioderma as Managing Director in charge of International Operations and the implementation of the company’s international strategic plan.

Jean-Yves started his career with consulting entity of Salustro Reddel then bought out by PricewaterhouseCoopers, spending three years working on M&A and restructuring projects in the health sector. Following this, Jean-Yves started working in the consumer health industry, namely with Laboratoires Fumouze (Church & Dwight) as Marketing Director, Laboratoires BMS as Africa & Middle East Manager for the Convatec Business Unit and then Darphin as Vice General Manager.

Jean-Yves currently serves as the Chairman of Italian manufacturer of aesthetic medicine, GPQ (WiQo), and Switzerland-based developer of generic drugs, Stragen, and as a Board Member of Canadian manufacturer of medical aesthetics products, Prollenium.